Acquired hemophilia A (AHA), a rare bleeding disorder caused by neutralizing
autoantibodies against coagulation factor VIII (FVIII), occurs in both men and women without …

To the Editor: Acquired hemophilia A (AHA) is a rare bleeding disorder caused by circulating
autoantibodies directed against clotting factor VIII (FVIII). 1, 2 It involves more frequently …

Acquired Haemophilia A is a rare acquired bleeding disorder caused by Factor VIII
autoantibodies, which neutralise FVIII activity. These inhibitors differ from alloantibodies …

Acquired hemophilia A (AHA) is due to autoantibodies against coagulation factor VIII (FVIII)
and most often presents with unexpected bleeding. In contrast to congenital hemophilia, the …

Emicizumab is a bispecific, humanized, monoclonal antibody mimicking the factor (F) VIII
cofactor activity in mediating the generation of FXa by FIXa in patients with hemophilia A …

Background Recombinant porcine factor VIII (rpFVIII, OBI‐1, susoctocog alfa) is used for the
treatment of acute bleeds in patients with acquired hemophilia A (AHA). Inhibitors in AHA …

Abstract Introduction Acquired hemophilia A (AHA) is caused by autoantibodies against
factor (F) VIII, and is characterized by severe, spontaneous bleeding, which can be life …

Background In 2016, a new recombinant B-domain deleted porcine FVIII (rpFVIII) was
licensed in Italy for the treatment of acquired haemophilia A (AHA), but only a few cases of …

Acquired hemophilia A (AHA) is a rare bleeding disorder in which acquired autoantibodies
to endogenous factor VIII (FVIII) decrease FVIII activity and lead to a bleeding phenotype. A …

La hemofilia adquirida (HA) es un trastorno hemostático autoinmune ocasionado por
autoanticuerpos dirigidos contra el factor VIII: C. En 52% de los casos, la causa se …